Nixon & Vanderhye RC.

11TH FLOOR 901 NORTH GLEBE ROAD ARLINGTON, VA 22203-1808

TELEPHONE: (703) 816-4000 FACSIMILE: (703) 816-4100

WRITER'S DIRECT DIAL NUMBER:

(703) 816-4091

FACSIMILE COVER SHEET PLEASE DELIVER IMMEDIATELY!!!!

Our Ref.:	3665-144	00E Do	da.	Fabruary 01, 2006					
Your Ref.:	Appln No. 10/534		ite: _	February 21, 2006					
_	Office of Initial Patent Examination's Filing Receipt								
To:		Corrections							
Firm:		USPTO							
Facsimile No.:	Facsimile No.: (703) 305-9822								
From:	B. J. Sadoff								

ATTACHMENT/S: Request for Correction of Filing Receipt and marked-up copy of Filing Receipt mailed 2/9/2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE						
In re Patei	nt Application of					
HALFON et al.		Atty. Ref.:	3665-144			
Serial No.	10/534,905	Group:	1614			
Filed:	May 16, 2005	Examiner:	Unknown			
For: F	С					

CONFIDENTIALITY NOTE The documents accompanying this facsimile transmission contain information belonging to Nixon & Vanderhye, which is confidential and/or legally privileged. This Information is only Intended for the use of the individual or entity named above. IF YOU ARE NOT THE NAMED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR TAKING OF THIS INFORMATION FOR ANY USE WHATSOEVER IS STRICTLY PROHIBITED. If you have received this facsimile in error, please immediately contact us by telephone to arrange for return of the original documents to us.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HALFON et al.

Atty. Ref.: 3665-144

Serial No. 10/534,905

TC/A.U.: 1614

Filed: May 16, 2005

Examiner: Unassigned

For: PYRROLIDINE DERIVATIVES FOR USE IN TREATING

HEPATITIS C VIRUS INFECTION

February 21, 2006

Office of Initial Patent Examination's **Filing Receipt Corrections** Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

VIA FACSIMILE (703) 305-9822

Sir:

REQUEST FOR CORRECTION OF FILING RECEIPT

The Office is requested to provide a Corrected Filing Receipt which indicates the title as "PYRROLIDINE DERIVATIVES FOR USE IN TREATING HEPATITIS C VIRUS INFECTION". A marked-up copy of the Filing Receipt mailed February 9, 2006, is attached wherein the changes are shown as hand-written text. The Office is requested to advise the undersigned if anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

B. J. Sadoff

Reg. No. 36,663

BJS:pp

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

NIXON & VANDERHYE PC





United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Passet and Tred mour Address COMMISSIONER FOR PATENTS 20. Box 1450 Abstraction, Viginia 22113-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY, DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/534,905	10/24/2005	1614	1230	3665-144	5	24	1

CONFIRMATION NO. 2300

FILING RECEIPT *OC000000017991872*

23117 **NIXON & VANDERHYE, PC** 901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203

Date Mailed: 02/09/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Philippe Halfon, Marseille, FRANCE; Chalom Sayada, Luxembourg, LUXEMBOURG; Jean-Marc Feryn, Marseille, FRANCE; Regis Perbost, Marseille, FRANCE; Frederic Garzino, Marseille, FRANCE; Michel Camplo, Marseille, FRANCE; Jerome Courcambeck, Marseille, FRANCE: Gerard Pepe, La Ciotat, FRANCE;

Assignment For Published Patent Application

GENOSCIENCE, Marseille, FRANCE

Power of Attorney: The patent practitioners associated with Customer Number 23117.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/IB03/04884 10/09/2003

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 02292487.2 10/09/2002

Projected Publication Date: 05/18/2006

Non-Publication Request: No

Early Publication Request: No

Title

hepatitis

Feb 21 2006 14:22

Pyrrolidine derivatives for use in treating heaptitie c virus infection

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT), An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

> LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED .

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The